Reliability of Her2/neu, estrogen receptor, and progesterone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients with primary and metastatic breast carcinoma

Diagnostic Cytopathology

Volumn 39, Issue 5, 2011, Pages 328-332

  Shabaik, Ahmed ^a,b   Lin, Grace ^a   Peterson, Michael ^a   Hasteh, Farnaz ^a   Tipps, Ann ^a   Datnow, Brian ^a   Weidner, Noel ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCSD MEDICAL CENTER   (United States)

Author keywords

cell block; ER; Her2; immunohistochemistry; PR

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; ASPIRATION BIOPSY; BREAST CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLOGY; EFFUSION; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; TISSUE SECTION;

EID: 79954510222     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.21389     Document Type: Article

References (19)

1. Natali PG, Nicotra MR, Bigotti A, et al. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer 1990; 45: 457-461. (Pubitemid 20087192)
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL,. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182. (Pubitemid 17231334)
3. Ross JS, Fletcher JA,. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol 1999; 112 (Suppl 1): S53-S67. (Pubitemid 30219464)
4. Ross JS, Fletcher JA,. The HER-2/neu oncogene: Prognostic factor, predictive factor and target for therapy. Semin Cancer Biol 1999; 9: 125-138. (Pubitemid 29265528)
5. Ross JS, Fletcher JA, Linette GP, et al. The Her-2/neu gene and protein in breast cancer 2003: Biomarker and target of therapy. Oncologist 2003; 8: 307-325. (Pubitemid 36929717)
6. Diaz NM,. Laboratory testing for HER2/neu in breast carcinoma: An evolving strategy to predict response to targeted therapy. Cancer Control 2001; 8: 415-418. (Pubitemid 32916872)
7. Payne SJ, Bowen RL, Jones JL, Wells CA,. Predictive markers in breast cancer-The present. Histopathology 2008; 52: 82-90. (Pubitemid 350265187)
8. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 966-978.
9. Kuukasjärvi T, Kononen J, Helin H, Holli K, Isola J,. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 1996; 14: 2584-2589. (Pubitemid 26300127)
10. Fetsch PA, Abati A,. The effects of antibody clone and pretreatment method on the results of HER2 immunostaining in cytologic samples of metastatic breast cancer: A query and a review of the literature. Diagn Cytopathol 2007; 35: 319-328. (Pubitemid 46835021)
11. Hanley KZ, Birdsong GG, Cohen C, Siddiqui MT,. Immunohistochemical detection of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast carcinomas: Comparison on cell block, needle-core, and tissue block preparations. Cancer Cytopathol 2009; 117: 279-288.
12. Williams SL, Birdsong GG, Cohen C, Siddiqui MT,. Immunohistochemical detection of estrogen and progesterone receptor and HER2 expression in breast carcinomas: Comparison of cell Block and tissue block preparations. Int J Clin Exp Pathol 2009; 2: 476-480.
13. Wixom CR, Albers EA, Weidner N,. Her2 amplification: Correlation of chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization. Appl Immunohistochem Mol Morphol 2004; 12: 248-251.
14. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 131: 18-43. (Pubitemid 46174133)
15. Krishnamurthy S, Dimashkieh H, Patel S, Sneige N,. Immunocytochemical evaluation of estrogen receptor on archival Papanicolaou-stained fine-needle aspirate smears. Diagn Cytopathol 2003; 29: 309-314. (Pubitemid 37493997)
16. Cano G, Milanezi F, Leitão D, Ricardo S, Brito MJ, Schmitt FC,. Estimation of hormone receptor status in fine-needle aspirates and paraffin-embedded sections from breast cancer using the novel rabbit monoclonal antibodies SP1 and SP2. Diagn Cytopathol 2003; 29: 207-211. (Pubitemid 37193648)
17. Moriki T, Takahashi T, Ueta S, Mitani M, Ichien M,. Hormone receptor status and HER2/neu overexpression determined by automated immunostainer on routinely fixed cytologic specimens from breast carcinoma: Correlation with histologic sections determinations and diagnostic pitfalls. Diagn Cytopathol 2004; 30: 251-256. (Pubitemid 38420243)
18. Beatty BG, Bryant R, Wang W, et al. HER-2/neu detection in fine-needle aspirates of breast cancer fluorescence in situ hybridization and immunocytochemical analysis. Am J Clin Pathol 2004; 122: 246-255. (Pubitemid 38971358)
19. Abati A, Simsir A,. Breast fine needle aspiration biopsy: Prevailing recommendations and contemporary practices. Clin Lab Med 2005; 25: 631-654. (Pubitemid 41674474)